R
Robert Schlegel
Researcher at Novartis
Publications - 49
Citations - 14422
Robert Schlegel is an academic researcher from Novartis. The author has contributed to research in topics: Cancer & Cervical cancer. The author has an hindex of 27, co-authored 49 publications receiving 11856 citations. Previous affiliations of Robert Schlegel include Millennium Pharmaceuticals & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina,Giordano Caponigro,Nicolas Stransky,Kavitha Venkatesan,Adam A. Margolin,Adam A. Margolin,Sungjoon Kim,Christine D. Wilson,Joseph Lehar,Gregory V. Kryukov,Dmitriy Sonkin,Anupama Reddy,Manway Liu,Lauren Murray,Michael F. Berger,Michael F. Berger,John Monahan,Paula Morais,Jodi Meltzer,Adam Korejwa,Judit Jané-Valbuena,Judit Jané-Valbuena,Felipa A. Mapa,Joseph Thibault,Eva Bric-Furlong,Pichai Raman,Aaron Shipway,Ingo H. Engels,Jill Cheng,Guoying K. Yu,Jianjun Yu,Peter Aspesi,Melanie de Silva,Kalpana Jagtap,Michael D. Jones,Li Wang,Charlie Hatton,Emanuele Palescandolo,Supriya Gupta,Scott Mahan,Carrie Sougnez,Robert C. Onofrio,Ted Liefeld,Laura E. MacConaill,Wendy Winckler,Michael R. Reich,Nanxin Li,Jill P. Mesirov,Stacey Gabriel,Gad Getz,Kristin G. Ardlie,Vivien W. Chan,Vic E. Myer,Barbara L. Weber,Jeffrey A. Porter,Markus Warmuth,Peter Finan,Jennifer L. Harris,Matthew Meyerson,Matthew Meyerson,Todd R. Golub,Michael Morrissey,William R. Sellers,Robert Schlegel,Levi A. Garraway,Levi A. Garraway +65 more
TL;DR: The results indicate that large, annotated cell-line collections may help to enable preclinical stratification schemata for anticancer agents and the generation of genetic predictions of drug response in the preclinical setting and their incorporation into cancer clinical trial design could speed the emergence of ‘personalized’ therapeutic regimens.
Journal ArticleDOI
Next-generation characterization of the Cancer Cell Line Encyclopedia
Mahmoud Ghandi,Franklin W. Huang,Franklin W. Huang,Franklin W. Huang,Judit Jané-Valbuena,Judit Jané-Valbuena,Gregory V. Kryukov,Christopher Lo,E. Robert McDonald,Jordi Barretina,Ellen Gelfand,Craig M. Bielski,Haoxin Li,Haoxin Li,Kevin Hu,Alexander Y. Andreev-Drakhlin,Jaegil Kim,Julian M. Hess,Brian J. Haas,François Aguet,Barbara A. Weir,Michael V. Rothberg,Brenton R. Paolella,Michael S. Lawrence,Rehan Akbani,Yiling Lu,Hong L. Tiv,Prafulla C. Gokhale,Antoine de Weck,Ali Amin Mansour,Coyin Oh,Juliann Shih,Kevin Hadi,Yanay Rosen,Jonathan Bistline,Kavitha Venkatesan,Anupama Reddy,Dmitriy Sonkin,Dmitriy Sonkin,Manway Liu,Joseph Lehar,Joshua M. Korn,Dale Porter,Michael D. Jones,Javad Golji,Giordano Caponigro,Jordan E. Taylor,Caitlin M. Dunning,Amanda L. Creech,Allison Warren,James M. McFarland,Mahdi Zamanighomi,Audrey Kauffmann,Nicolas Stransky,Marcin Imielinski,Yosef E. Maruvka,Yosef E. Maruvka,Andrew D. Cherniack,Andrew D. Cherniack,Aviad Tsherniak,Francisca Vazquez,Jacob D. Jaffe,Andrew A. Lane,David M. Weinstock,Cory M. Johannessen,Michael Morrissey,Frank Stegmeier,Robert Schlegel,William C. Hahn,William C. Hahn,Gad Getz,Gordon B. Mills,Jesse S. Boehm,Todd R. Golub,Todd R. Golub,Todd R. Golub,Levi A. Garraway,Levi A. Garraway,William R. Sellers,William R. Sellers +79 more
TL;DR: The original Cancer Cell Line Encyclopedia is expanded with deeper characterization of over 1,000 cell lines, including genomic, transcriptomic, and proteomic data, and integration with drug-sensitivity and gene-dependency data, which reveals potential targets for cancer drugs and associated biomarkers.
Journal ArticleDOI
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen,Jesse S. Boehm,So Young Kim,Sapana R. Thomas,Sapana R. Thomas,Leslie Wardwell,Laura A. Johnson,Laura A. Johnson,Caroline Emery,Nicolas Stransky,Alexandria P. Cogdill,Jordi Barretina,Jordi Barretina,Giordano Caponigro,Haley Hieronymus,Haley Hieronymus,Haley Hieronymus,Ryan R. Murray,Kourosh Salehi-Ashtiani,David E. Hill,Marc Vidal,Jean J. Zhao,Xiaoping Yang,Ozan Alkan,Sungjoon Kim,Jennifer L. Harris,Christine D. Wilson,Vic E. Myer,Peter Finan,David E. Root,Thomas M. Roberts,Todd R. Golub,Todd R. Golub,Keith T. Flaherty,Reinhard Dummer,Barbara L. Weber,William R. Sellers,Robert Schlegel,Jennifer A. Wargo,William C. Hahn,William C. Hahn,Levi A. Garraway,Levi A. Garraway +42 more
TL;DR: Together, these results provide new insights into resistance mechanisms involving the MAPK pathway and articulate an integrative approach through which high-throughput functional screens may inform the development of novel therapeutic strategies.
Journal ArticleDOI
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors
Garrett M. Frampton,Siraj M. Ali,Margaret Rosenzweig,Juliann Chmielecki,Xinyuan Lu,Todd M. Bauer,Mikhail Akimov,Jose A. Bufill,Carrie B. Lee,David Jentz,Rick Hoover,Sai-Hong Ignatius Ou,Ravi Salgia,Tim Brennan,Zachary R. Chalmers,Savina Jaeger,Alan Huang,Julia A. Elvin,Rachel L. Erlich,Alex Fichtenholtz,Kyle Gowen,Joel R. Greenbowe,Adrienne Johnson,Depinder Khaira,Caitlin McMahon,Eric M. Sanford,Steven Roels,Jared White,Joel Greshock,Robert Schlegel,Doron Lipson,Roman Yelensky,Deborah Morosini,Jeffrey S. Ross,Eric A. Collisson,Malte Peters,Philip J. Stephens,Vincent A. Miller +37 more
TL;DR: Analysis of tumor genomic profiles from 38,028 patients is reported to identify 221 cases with METex14 mutations, including 126 distinct sequence variants, and identify a unique subset of patients likely to derive benefit from MET inhibitors.
Journal ArticleDOI
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Sauveur-Michel Maira,Sabina Pecchi,Alan Huang,Matthew Burger,Mark Knapp,Dario Sterker,Christian Schnell,Daniel Guthy,Tobi Nagel,Marion Wiesmann,Saskia M. Brachmann,Christine Fritsch,Marion Dorsch,Patrick Chène,Kevin Shoemaker,Alain De Pover,Daniel Menezes,Georg Martiny-Baron,Doriano Fabbro,Christine D. Wilson,Robert Schlegel,Francesco Hofmann,Carlos Garcia-Echeverria,William R. Sellers,Charles Voliva +24 more
TL;DR: The biologic characterization of the 2-morpholino pyrimidine derivative pan-PI3K inhibitor NVP-BKM120 shows dose-dependent in vivo pharmacodynamic activity as measured by significant inhibition of p-Akt and tumor growth inhibition in mechanistic xenograft models and behaves synergistically when combined with either targeted agentssuch as MEK or HER2 inhibitors or with cytotoxic agents such as docetaxel or temozolomide.